Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.
Key PointsSubstantial revenue from its flagship drug Casgevy should be right around the corner.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.